CELL INTELLIGENCE · 肿瘤细胞治疗研究

CELLIN 肿瘤细胞治疗研究

← 返回

将嵌合抗原受体（CAR）T 细胞武装为肿瘤治疗微药房

英文原题：Armoring chimeric antigen receptor (CAR) T cells as micropharmacies for cancer therapy.

查看英文原题

Armoring chimeric antigen receptor (CAR) T cells as micropharmacies for cancer therapy.

PubMed 2024/09/25（内容时间） Immunooncol Technol

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

技术：CAR-T地区：欧洲
登录后收藏与关注 全文解读登录并开通会员后使用加入对比登录并开通会员后使用

中文摘要

嵌合抗原受体（CAR）T细胞疗法已成为抗癌的有力武器。然而，肿瘤浸润有限、抗原逃逸以及肿瘤微环境中的免疫抑制等挑战常会削弱其疗效。本文综述了装甲型CAR-T 细胞（又称“微型药厂”）克服这些障碍、增强过继性T细胞（ATC）治疗效果的潜力。文章探讨了这些先进疗法背后的工程化策略，以及它们提高CAR-T 细胞疗效的机制。此外，还讨论了该领域最新进展和研究发现，以全面阐释装甲型CAR-T 细胞在癌症治疗中的作用。综上，本文凸显了将微型药厂整合至ATC治疗中的广阔前景，有望推动开发更有效、更具靶向性的癌症疗法。

展开英文摘要原文

Chimeric antigen receptor (CAR)-T-cell therapy has emerged as a powerful weapon in the fight against cancer.

However, its efficacy is often hindered by challenges such as limited tumor penetration, antigen escape, and immune suppression within the tumor microenvironment. This review explores the potential of armored CAR-T cells, or 'micropharmacies', in overcoming these obstacles and enhancing the therapeutic outcomes of adoptive T-cell (ATC) therapy.

We delve into the engineering strategies behind these advanced therapies and the mechanisms through which they improve CAR-T-cell efficacy.

Additionally, we discuss the latest advancements and research findings in the field, providing a comprehensive understanding of the role of armored CAR-T cells in cancer treatment. Ultimately, this review highlights the promising future of integrating micropharmacies into ATC therapy, paving the way for more effective and targeted cancer treatments.

论文信息

作者
Carcopino C、Erdogan E、Henrich M、Kobold S
单位
Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, Ludwig Maximilian University (LMU) of Munich, Munich, Germany.Germany
文献类型
综述
期刊
Immuno-oncology technology2024 Dec
原文标识
PubMed 39711794　·　DOI 10.1016/j.iotech.2024.100739

在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →